Fewer than 10% of individuals eligible to benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it releases its initial advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for more widespread and fairer availability to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that excess weight is a lifelong illness that can be addressed with holistic and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key hurdles to widespread access to the injections that can assist patients in reducing considerable body mass, notes the agency.
Skinny Jab Shortage
Despite the present most optimistic scenario, the manufacturing of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The recommendation encourages governments and firms to increase availability, through measures like patent sharing.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is due to expire in a number of countries in 2026.
The Way Weight-Loss Injections Function
These medications imitate a natural hormone to slow digestion, suppress the appetite and enhance satiety so people reduce food intake.
People typically start to lose weight within a few weeks of commencing the once-weekly jabs.
Research points to people may see weight return after a year of stopping the drug, because their normal hunger resume.
To be overweight or obese elevates your chance for experiencing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight impacts individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.
